Shanghai Fosun Pharmaceutical (Group) Co (Shanghai Fosun Pharmaceutical (Group) Co) Return-on-Tangible-Equity : 13.73% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Shanghai Fosun Pharmaceutical (Group) Co's annualized net income for the quarter that ended in Mar. 2024 was $339 Mil. Shanghai Fosun Pharmaceutical (Group) Co's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $2,467 Mil. Therefore, Shanghai Fosun Pharmaceutical (Group) Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was 13.73%.

The historical rank and industry rank for Shanghai Fosun Pharmaceutical (Group) Co's Return-on-Tangible-Equity or its related term are showing as below:

SFOSF' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.08 Med: 23.86 Max: 30.42
Current: 11.08

During the past 13 years, Shanghai Fosun Pharmaceutical (Group) Co's highest Return-on-Tangible-Equity was 30.42%. The lowest was 11.08%. And the median was 23.86%.

SFOSF's Return-on-Tangible-Equity is ranked better than
63.02% of 933 companies
in the Drug Manufacturers industry
Industry Median: 6.33 vs SFOSF: 11.08

Shanghai Fosun Pharmaceutical (Group) Co Return-on-Tangible-Equity Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Return-on-Tangible-Equity Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Return-on-Tangible-Equity

Get a 7-Day Free Trial

30.16

26.24

28.88

20.60

13.18

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Return-on-Tangible-Equity	Get a 7-Day Free Trial															21.13	16.74	11.11	2.34	13.73

Competitive Comparison of Shanghai Fosun Pharmaceutical (Group) Co's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Fosun Pharmaceutical (Group) Co's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fosun Pharmaceutical (Group) Co's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Shanghai Fosun Pharmaceutical (Group) Co's Return-on-Tangible-Equity falls into.

Shanghai Fosun Pharmaceutical (Group) Co Return-on-Tangible-Equity Calculation

Shanghai Fosun Pharmaceutical (Group) Co's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity	=	Net Income	/	( (Total Tangible Equity	+	Total Tangible Equity)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	Net Income	/	( (Total Stockholders Equity - Intangible Assets	+	Total Stockholders Equity - Intangible Assets )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	334.202	/	( (2627.779	+	2444.559 )	/ 2 )
	=	334.202	/	2536.169
	=	13.18 %

Shanghai Fosun Pharmaceutical (Group) Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity	=	Net Income	/	( (Total Tangible Equity	+	Total Tangible Equity)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	Net Income	/	( (Total Stockholders Equity - Intangible Assets	+	Total Stockholders Equity - Intangible Assets)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	338.672	/	( (2444.559	+	2489.419)	/ 2 )
	=	338.672	/	2466.989
	=	13.73 %

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

Shanghai Fosun Pharmaceutical (Group) Co (OTCPK:SFOSF) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.

Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.

Shanghai Fosun Pharmaceutical (Group) Co Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Fosun Pharmaceutical (Group) Co (Shanghai Fosun Pharmaceutical (Group) Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (OTCPK:SFOSF) » Definitions » Return-on-Tangible-Equity

Traded in Other Exchanges

02196:Hong Kong 08HH:Germany 08HH:Germany 600196:China

Address

No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233

Website

https://www.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.